The rise of psychedelic therapeutics for end-of-life care: A new frontier in mental health and palliative medicine
09/08/25 at 03:00 AM
The rise of psychedelic therapeutics for end-of-life care: A new frontier in mental health and palliative medicine
AI Invest; by Julian Cruz; 9/3/25
Aime Summary
- Psilocybin therapy shows 35.15% anxiety reduction in end-of-life care trials, driving FDA Breakthrough Therapy designations and state-level regulatory reforms.
- Canada's Quebec and U.S. states like Oregon/Colorado establish psilocybin access frameworks, with Oregon issuing 374 facilitator permits by 2025.
- Psychedelics market valued at $7.4B in 2025 projects 15% CAGR to $22.6B by 2033, led by Cybin, Compass Pathways, and infrastructure providers like Psyence BioMed.
- Patient advocacy groups secure policy wins (e.g., Oregon HB2387) while challenges persist in insurance coverage and practitioner training despite regulatory progress.